Picture [LSA] – The Business Web Portal 650x89px
Document › Details

bioMérieux S.A.. (4/19/18). "Press Release: bioMérieux – First-Quarter 2018 Business Review".

Organisations Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
  Organisation 2 Astute Medical Inc.
  Group Mérieux (Group)
Products Product in vitro diagnostics (IVD)
  Product 2 immunoassay (diagnostics, antibody-antigen-test)
Index term Index term Astute Medical–Mérieux: investment, 201804 acquisition $90m in cash by bioMérieux
Person Person Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)

> Strong sales dynamic in first-quarter 2018, with sales up 12.5% at constant exchange rates and scope of consolidation:

>> €587 million in sales
>> Up 3.4% as reported

> Growth driven by molecular biology in the context of an intense flu season in the United States, and by buoyant business in the Asia-Pacific region

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In the first quarter, bioMérieux delivered a sound commercial performance. The recent acquisition of Astute Medical will strengthen bioMérieux’s commitment and position in immunoassays and is a perfect fit with our strategy of developing high medical value tests in order to improve patient care.”

Download [ FULL RELEASE at ]

Record changed: 2018-05-28


Picture [LSA] – The Business Web Portal 650x89px

More documents for Mérieux (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top